A B S T R A C T Lymphocytes from a healthy HLA-identical bone marrow transplant donor were tested for their ability to destroy her brother's acute myelogenous leukemia blasts in vitro. Primary mixed lymphocyte culture (MLC) and cell-mediated lysis (CML) responses between the patient's remission (pretransplant) and donor's lymphocytes were negative. Stimulation of donor lymphocytes for 7 d in vitro with irradiated leukemia cells, leukemia cells plus allogeneic irradiated lymphocytes, or a pool of irradiated lymphocytes from 10 donors, did not activate any cytotoxic cells able to destroy the HLA identical leukemic blasts. Further culturing for 7 additional d in T cell growth factor (TCGF) generated lymphocytes that induced effective cytotoxicity against the leukemic blasts, but not against autologous lymphocytes. Effective killing against the leukemia was observed only in cultures initially stimulated with the irradiated leukemia cells. These cytotoxic cells were maintained in TCGF and mediated persistent killing against the leukemic target cells. They were also able to destroy lymphocytes from the patient's mother and father, but not from an unrelated cell donor. This suggested specific recognition of non-HLA antigens inherited by the patient, that were foreign to the HLA identical bone marrow donor. These lymphocytes were cloned by a limiting dilution technique and one clone maintained cytotoxicity to the AML blasts and the father's lymphocytes, but not lymphocytes from the mother or an HLA-identical donor.
INTRODUCTION
Human lymphocytes are readily activated in vitro by histocompatibility antigens controlled by the HLA region (1, 2) . Lymphocytes from healthy donors who have never been directly immunized with foreign tissue mount a rapid proliferative response to foreign HLA-D antigens in the mixed lymphocyte culture (MLC)' and generate highly reactive cytotoxic T lymphocytes (T,) that recognize antigens controlled by the HLA A, B, and C regions (3) . In contrast, lymphocytes from healthy HLA-identical siblings do not induce either an MLC proliferative response nor the generation of cytotoxic cells that react to each others tissues in vitro (4) . However, tissue grafts from one HLA identical sibling to another are rejected when immune suppression is omitted. Thus the "weak" minor histocompatibility antigens that can affect graft rejection in vivo are not recognized by human lymphocyte populations in a primary in vitro response (5) .
In the mouse, primary responses to minor locus (non-H-2) antigens are observed between some strains (6) . Priming in vivo increases the ability to detect a minor locus immune response in vitro (7) . Recognition of these minor locus antigens is H-2 restricted, since the T, must simultaneously recognize H-2 antigens (8, 9) .
Furthermore, depletion of suppressor lymphocyte populations results in a population that gives an enhanced response to minor locus antigens in vitro (10) . In man, in vivo immunization, either by multiple transfusions, or tissue grafting, has provided adequate sensitization to enable the detection of in vitro immune responses to minor locus transplantation antigens (11) (12) (13) . These cytotoxic cells are also MHC restricted (14, 15) .
We have studied the in vitro responses of human lymphocytes to HLA-identical leukemic myeloblasts. Prior Generation of conditioned medium containing T cell growth factor (TCGF). Pooled irradiated PBL from eight separate donors were cultured at 106 cells/ml in the presence of 1% phytohemagglutinin (Difco Laboratories, Detroit, MI). Supernatant was harvested after 48 h, filtered, and tested for potency by previously described methods (19, 20) . Such unpurified supernatants are known to contain many lymphokines, some of which influence T cells, including interleukin-2 (19) (20) (21) (22) . This conditioned medium was used here to expand and clone human T cell populations; it is designated "TCGF" (19) (20) (21) (22) (23) (24) (25) to functionally distinguish it from the multiple other forms of conditioned medium that have been described.
In vitro cultures, MLC and cell-mediated lysis (CML) assays. MLC. The MLC was performed using conditions described previously (26 dimethyl sulfoxide using controlled rate freezing (Cryo-Med, Mt. Clemens, MI) as described previously (16, 30) .
RESULTS
A previously healthy 26-yr-old man (P) was diagnosed with acute myelogenous leukemia (by standard histologic criteria) in June 1981. Before any antileukemic therapy, an aliquot of his leukemic bone marrow (L) was aspirated, purified, and cryopreserved. Immunologic marker testing on these myeloblasts revealed they were typical AML cells; negative for terminal deoxynucleotidyl transferase, the "common" acute lymphoblastic leukemia antigen, and T and B cell markers, but heterogeneous for the Ia antigen (31). 4 sensitization, these lymphocytes were tested for their cytotoxic capacity in the CML assay using leukemic blasts as target cells as well as other populations of target cells (Table II , experiment 1). Note that sensitization of the sister's lymphocytes with irradiated allogeneic cells (SXX or S Pool,) generated effective Tc directed against alloantigens present on target cells from unrelated donor X. However, neither of these cultures generated effective killing against the leukemic blasts (32) . Even sensitization in the "three cell" protocol (SLXXX) generated no killing of the leukemic blasts (16, 17) . However, this same culture was able to kill the allogeneic cells from donor X, demonstrating that immune activation had occurred in this culture. Lastly, lymphocytes from a second unrelated donor (Y) were sensitized with irradiated leukemic cells. This culture (YL5) generated effective killing against the leukemic blasts, as well as against remission bone marrow cells from the patient, and lymphocytes from the healthy sibling. Thus, the leukemic blasts were effective at presenting alloantigens in a sensitization culture. Furthermore, the leukemic blasts, remission bone marrow, and sibling's lymphocytes could be destroyed by appropriately alloactivated killer cells recognizing the identical HLA antigens on these three target cells.
Replicate flasks of these same cultures were maintained in vitro in fresh media containing 20% TCGF. These were retested on the same target populations 7 d later (Table II, experiment 2). As noted in the primary cultures, alloactivation of sibling's (S) lymphocytes with irradiated pooled lymphocytes or cells from donor X induced T, that effectively destroyed target lymphocytes from donor X. However, activation with the HLA identical leukemic blasts, alone (SL5) or in combination with the irradiated allogenic cells (SLXXX), now induced 26.3 and 32.8% killing against the leukemic blasts. These same two effector cell populations also mediated weak killing against remission bone marrow (11.6% and 13.1% cytotoxicity), but were unable to destroy the sister's autologous lymphocytes.
Destruction of the leukemic cells and "remission" bone marrow by HLA identical sibling's lymphocytes could result from Tc recognition of minor locus (non-HLA) antigens present on both tissues, or from T, de- (Table III) . As before, the sister's effector population that had been alloactivated (SXx) was still highly efficient at destroying target cells from donor X. There was low level cross-reactive killing of this effector population on the mother's target cells and minimal cytotoxicity against the father's target cells. Minimal detectable cytotoxicity was seen against autologous lymphocytes from the sister or against the leukemic blasts by these alloactivated cytotoxic cells. In contrast, the leukemia cells were effectively destroyed by the sister's cells that had been activated with leukemic blasts (SL1). This culture also mediated excellent killing against both mother's and father's target cells, but not against autologous lymphocytes (S) or cells from donor X.
To further examine the specificity of this Tc response, T, clones were generated and maintained in vitro (23 Cells from T, clones 11 and 17 (see text) were assayed on the indicated target cells in the 4-h StCr release assay: L, AML blasts; S, M, and F are PBL from the patient's sister, mother, and father, respectively. Because of low effector cell yields, clone 11 was tested at 0.1 effector per target cell and clone 17 was tested at 1.0 effector per target cell.
DISCUSSION
These experiments demonstrate that under appropriate in vitro sensitization conditions, effector cells able to destroy HLA identical leukemic blasts can be generated and maintained in vitro, cryopreserved, thawed, recultured, cloned, and still retain their cytotoxic function and immunologic specificity. We feel that results presented in Table III demonstrate that non-HLA antigens are being recognized by the sister's lymphocytes that had been activated in vitro with irradiated leukemic cells and expanded with TCGF. The absence of killing by this population on autologous lymphocytes and target cells from donor X argues strongly against this being a totally "nonspecific" effector cell. In contrast, the activation of killing against the leukemic target might suggest the recognition of a leukemia specific antigen. But if this were the case, then this (SL1) population should not have destroyed nonleukemic target lymphocytes from the mother and father. This latter effect could occur only if leukemia-specific antigens on the leukemic blasts are immunologically cross-reactive with foreign histocompatibility antigens on the mother's and father's normal lymphoid cells (this phenomenon has been designated "alien" histocompatibility antigens on tumor cells) (33) . However, if this were the case, one would expect even greater killing of the unrelated X target cells by the SL. culture since there is twice as great a chance of cross-reactivity on the target cells from unrelated donor X than on target cells from either the mother or father. This is due to donor X differing from the responding lym-AML Blasts and TCGF Induce Non-HLA Recognition by T Cells In Vitro Bortin, 1983 , J. Cell. Biochem., 7A: 78, (Abstr.), 41). Thus, the "graft vs. leukemia" response may actually represent preferential destruction of leukemic blasts by minor locus reactive lymphocytes.
Current in vitro methods now make it possible to grow adequate numbers of human lymphocytes for potential adoptive immunotherapy (33) . Preliminary testing shows no significant toxicity in primates or human patients of T cells grown in TCGF (42, 43 
